Strategies for the modulation of mitochondrial metabolism and activity in the treatment of neurodegenerative diseases: A systematic review and meta-analysis.

This systematic review and meta-analysis demonstrates that zebrafish models, combined with computational tools, offer a cost-effective and efficient strategy for screening and repurposing compounds targeting mitochondrial dysfunction to treat various neurodegenerative diseases.

The Gist

Imagine your body is a bustling city. In this city, every building (your cells) needs electricity to stay lit and functional. The power plants that generate this electricity are called mitochondria.

In Neurodegenerative Diseases (like Alzheimer's, Parkinson's, or ALS), the power plants in the brain's buildings start to break down. The lights flicker, the elevators stop working, and eventually, the buildings collapse. This leads to memory loss, shaking, and the inability to move.

For a long time, scientists have been trying to fix these power plants, but they've been using a very expensive, slow, and difficult method: testing new "fix-it" chemicals on mice. Mice are great, but they are pricey, take a long time to grow up, and sometimes their brains don't act exactly like human brains.

The New Hero: The Zebrafish

Enter the Zebrafish. Think of these tiny, transparent fish as the "smart, fast, and affordable interns" of the scientific world.

• They are tiny: You can fit thousands in a small tank.
• They are transparent: When they are babies, you can actually see their brains and power plants working through their skin, like looking through a glass window.
• They are related to us: About 70% of their DNA is the same as ours.
• They grow fast: They go from egg to adult in a few weeks, not months.

What This Paper Did

The authors of this study decided to take a "big picture" look at all the recent research where scientists used these zebrafish interns to test new drugs for brain diseases. They didn't just look at one study; they gathered 34 different studies and analyzed 37 different "fix-it" compounds (drugs).

Think of it like a super-market audit. Instead of checking one store, they checked 34 stores to see which products (drugs) were actually helping the power plants (mitochondria) in the fish brains.

What They Found

Here is the breakdown of their discovery, translated into everyday terms:

1. Nature is the Best Pharmacist
Most of the successful "fix-it" chemicals they found came from nature.

• The Analogy: Imagine trying to fix a broken engine. You could try to build a new part from scratch in a lab (Synthetic), or you could look at what nature has already perfected over millions of years.
• The Result: About 77% of the promising drugs came from plants, fungi, or animals. Things like Berberine (from a plant), Naringenin (found in citrus), and Quercetin (in onions and apples) were stars in the fish tanks. They acted like a mechanic tuning up the engine, cleaning out the gunk (oxidative stress), and getting the power flowing again.

2. The "Parkinson's" Obsession
The researchers noticed that almost 60% of the studies were focused on Parkinson's Disease.

• Why? Parkinson's is like a specific type of power failure where the "dopamine" lights go out. It's the second most common brain disease, and because mice models for Parkinson's are tricky to get right, scientists are turning to zebrafish to find a better solution faster.

3. The "Magic" Mechanism: Mitophagy
One of the most popular ways these drugs worked was by triggering Mitophagy.

• The Analogy: Imagine your power plant gets covered in trash and broken parts. Instead of building a whole new plant, the cell has a "garbage truck" system called mitophagy that sweeps out the broken parts and recycles them.
• The Result: Many of these natural drugs told the fish cells, "Hey, clean house! Throw out the broken mitochondria and make new ones."

4. The Computer Crystal Ball (Meta-Analysis)
The authors didn't just stop at looking at the fish. They used powerful computer software to map out how these drugs interact with human genes.

• The Analogy: Imagine you have a map of the city's power grid. The computer looked at the drugs and said, "Hey, this drug that fixes Parkinson's in fish also talks to a gene that causes ALS or Alzheimer's."
• The Result: This allowed them to suggest Drug Repurposing. For example, they found that a drug being tested for one disease might actually be a perfect fit for a different disease because they share the same broken wiring in the brain.

The Big Takeaway

This paper is a huge green light for using Zebrafish as the primary testing ground for brain diseases.

• Old Way: Test on mice $\rightarrow$ Expensive $\rightarrow$ Slow $\rightarrow$ Sometimes fails to predict human results.
• New Way: Test on Zebrafish $\rightarrow$ Cheap $\rightarrow$ Fast $\rightarrow$ Transparent (we can see the results) $\rightarrow$ High success rate.

In short: The authors are saying, "Stop wasting time and money on slow methods. Use these tiny, transparent fish and nature's own pharmacy to find cures for brain diseases much faster. And use computers to connect the dots between different diseases, because a cure for one might just be a cure for another."

It's a shift from "guessing and checking" to "smart, fast, and nature-guided" discovery.

Technical Summary

1. Problem Statement

Neurodegenerative diseases (NDDs), including Alzheimer's, Parkinson's, ALS, and Huntington's, are increasing in prevalence due to global population aging. A common pathological feature across many NDDs is mitochondrial dysfunction. While targeting mitochondrial metabolism offers a promising therapeutic strategy, current drug discovery relies heavily on rodent models, which are costly, time-consuming, and often fail to fully replicate human symptomatology (particularly in Parkinson's disease). There is an urgent need for cost-effective, high-throughput alternatives to accelerate the identification of novel therapies.

2. Methodology

The study employed a rigorous Systematic Review and Meta-Analysis following the PRISMA 2020 guidelines.

• Search Strategy: A comprehensive search was conducted across four databases (PubMed, Embase, Scopus, Web of Science) in December 2024. The search query combined keywords: mitochondrial metabolism, therapy, neurodegenerative diseases, and zebrafish.
• Selection Criteria:
  • Inclusion: English-language articles, full-text availability, studies using zebrafish (Danio rerio) models, and compounds targeting mitochondrial metabolism for NDDs.
  • Exclusion: Reviews, editorials, non-English papers, and studies focusing on non-NDD pathologies (e.g., cancer, aging alone).
• Data Extraction & Quality Assessment:
  • Two independent reviewers extracted data on compounds, mechanisms, and disease models.
  • Risk of Bias: Assessed using the SYRCLE (Systematic Review Centre for Laboratory Animal Experimentation) tool, scoring studies on 10 items (e.g., randomization, blinding, allocation concealment).
• Meta-Analysis & Network Construction:
  • Drug-Gene Interactions: Data was retrieved from the Drug Gene Interaction Database (DGIdb).
  • Network Analysis: A tripartite network (Gene-Compound-Disease) was constructed. Disease-gene bipartite networks were derived to analyze connectivity.
  • Functional Enrichment: Gene enrichment meta-analysis was performed to identify specific cellular pathways and locations associated with each disease.

3. Key Contributions

• Comprehensive Zebrafish Overview: This is the first systematic review to specifically aggregate data on zebrafish assays used to screen compounds modulating mitochondrial metabolism for NDDs.
• Compound Characterization: The study cataloged 37 distinct compounds tested across 9 different NDDs, categorizing them by chemical origin (natural, synthetic, semisynthetic, etc.).
• Computational Integration: By integrating experimental data with DGIdb and network analysis, the authors moved beyond simple literature summarization to predict drug repurposing opportunities and identify novel gene targets.
• Quality Benchmarking: The study provides a critical assessment of the methodological quality of current zebrafish NDD research, highlighting specific gaps (e.g., lack of blinding).

4. Key Results

A. Study Selection and Quality

• Selection: From 176 initial entries, 34 studies were included, covering 37 compounds.
• Quality Assessment: The average quality score was 3.29/10. Major limitations included a lack of blinding (only 14.7% of studies blinded caregivers/investigators) and random housing. However, reporting bias was low (100% of studies reported outcomes without selection bias).

B. Compound Characteristics

• Origins: The majority of compounds were exogenous (77%), primarily plant-derived (33%), followed by synthetic (13%) and semisynthetic (15%). Only 23% were endogenous metabolites (e.g., Coenzyme Q10, Neuroglobin).
• Mechanisms: The most frequently targeted mechanism was mitophagy (ubiquitin-dependent and receptor-mediated). Other mechanisms included modulation of the mitochondrial respiratory chain, reduction of oxidative stress, and regulation of apoptosis.
• Disease Focus: Parkinson's Disease (PD) dominated the research landscape, accounting for 22 out of 37 compounds (58%). Other diseases included Huntington's (4), Leigh syndrome (3), and ALS (2).

C. Meta-Analysis and Network Findings

• Tripartite Network: The analysis identified highly connected genes, notably CYP3A4, CYP1A2, CYP2C19, CYP2D6 (Cytochrome P450 family), ATAD5, CFTR, E2F1, and GFAP.
• Disease-Specific Pathways:
  • Parkinson's: Linked to calcium-dependent channels.
  • Huntington's: Associated with membrane regions (basal/basolateral).
  • ALS: Linked to caveolae and nuclear membranes.
  • Leigh Syndrome: Associated with endocytosis/exocytosis vesicles.
  • Alzheimer's: Linked to ATPases.
• Drug Repurposing Insights:
  • Creatine: Strongly interacts with MOBP (linked to ALS) but was studied for Huntington's, suggesting potential repurposing for ALS.
  • Terazosin: Studied for ALS but interacts with HTT (Huntingtin), suggesting potential for Huntington's disease.
  • Apigenin/Nimodipine/Entinostat: Interact with CFTR (linked to Adrenoleukodystrophy), suggesting these PD-focused drugs could be explored for ALD.

5. Significance and Conclusion

• Validation of Zebrafish Models: The review confirms zebrafish as a superior, cost-effective model for high-throughput screening of mitochondrial modulators, particularly for NDDs where rodent models struggle to replicate specific symptomatology (e.g., PD progression).
• Therapeutic Potential: The identification of 37 compounds, many of natural origin, provides a robust pipeline for future drug development. The focus on mitochondrial regulation offers a unified therapeutic strategy across diverse NDDs.
• Computational Guidance: The meta-analysis demonstrates that computational tools can effectively predict drug-gene-disease relationships, enabling the repurposing of existing drugs (e.g., using ALS drugs for Huntington's) before costly experimental validation.
• Future Directions: The authors emphasize the need for improved methodological rigor in future animal studies (specifically blinding and randomization) and advocate for the integration of computational network analysis to accelerate the discovery of disease-modifying therapies.